Publications 2024

Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW (2024)
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891

Gehin JE, Klaasen RA, Klami Kristianslund E, Jyssum I, Sexton J, Warren DJ, Aletaha D, Haavardsholm EA, Syversen SW, Goll GL, Bolstad N (2024)
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
RMD Open, 10 (4)
DOI 10.1136/rmdopen-2024-004888, PubMed 39537558

Jyssum I, Gehin JE, Sexton J, Kristianslund EK, Hu Y, Warren DJ, Kvien TK, Haavardsholm EA, Syversen SW, Bolstad N, Goll GL (2024)
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Rheumatology (Oxford), 63 (6), 1746-1755
DOI 10.1093/rheumatology/kead525, PubMed 37773994

Kawano-Dourado L, Kristianslund EK, Zeraatkar D, Jani M, Makharia G, Hazlewood G, Smith C, Jess T, Stabell C, Schatten A, Owen A, Gehin J, Katsidzira L, Weinberg D, Bauer-Ventura I, Tugwell P, Moayyedi P, Cecchi AVW, Shimabuco A, Seterelv S, Gyuatt G, Agoritsas T, Vandvik PO (2024)
Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline
BMJ, 387, e079830
DOI 10.1136/bmj-2024-079830, PubMed 39467592

Martínez-Feito A, Plasencia-Rodríguez C, Novella-Navarro M, Gehin JE, Hernández-Breijo B, Brenis CM, Villalba-Yllán A, Fernández E, Monjo-Henry I, Pascual-Salcedo D, Nozal P, Balsa A (2024)
Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis
Clin Exp Rheumatol, 42 (5), 999-1005
DOI 10.55563/clinexprheumatol/ig40gm, PubMed 38197184

Nome RV, Paus E, Gehin JE, Bolstad N, Bjøro T (2024)
Managing hemolysis in serum neuron-specific enolase measurements - an automated algorithm for routine practice
Scand J Clin Lab Invest, 84 (4), 225-229
DOI 10.1080/00365513.2024.2359091, PubMed 38853575

Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, Pérez De Diego R, Bonilla G, Gehin JE, Villalba-Yllán A, Nuño L, Pascual-Salcedo D, Nozal P, Almirón MD, Balsa A (2024)
Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients
Front Med (Lausanne), 11, 1461396
DOI 10.3389/fmed.2024.1461396, PubMed 39296891

Syversen SW, Gehin JE, Goll GL, Bolstad N, Haavardsholm EA, Lillegraven S (2024)
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
Arthritis Rheumatol, 76 (5), 667-669
DOI 10.1002/art.42764, PubMed 37984460

Publications 2023

Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW (2023)
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323

Publications 2022

Brun MK, Goll GL, Jørgensen KK, Sexton J, Gehin JE, Sandanger Ø, Olsen IC, Klaasen RA, Warren DJ, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW (2022)
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981

Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW (2022)
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
BioDrugs, 36 (6), 731-748
DOI 10.1007/s40259-022-00559-1, PubMed 36315391

Krieckaert C, Hernández-Breijo B, Gehin JE, le Mélédo G, Balsa A, Jani M, Mulleman D, Navarro-Compan V, Wolbink G, Isaac J, van Tubergen A (2022)
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002216, PubMed 35980738

Krieckaert CL, van Tubergen A, Gehin JE, Hernández-Breijo B, Le Mélédo G, Balsa A, Böhm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Compán V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD (2022)
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Ann Rheum Dis, 82 (1), 65-73
DOI 10.1136/annrheumdis-2022-222155, PubMed 35551063

Publications 2021

Gehin JE, Klaasen RA, Norli ES, Warren DJ, Syversen SW, Goll GL, Bjøro T, Kvien TK, Mjaavatten MD, Bolstad N (2021)
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
Rheumatol Int, 41 (9), 1657-1665
DOI 10.1007/s00296-021-04865-9, PubMed 33944985

Gehin JE, Syversen SW, Warren DJ, Goll GL, Sexton J, Bolstad N, Hammer HB (2021)
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
RMD Open, 7 (3)
DOI 10.1136/rmdopen-2021-001985, PubMed 34911811

Gehin JE, Warren DJ, Syversen SW, Lie E, Sexton J, Loli L, Wierød A, Bjøro T, Kvien TK, Bolstad N, Goll GL (2021)
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Scand J Rheumatol, 50 (6), 445-454
DOI 10.1080/03009742.2021.1875040, PubMed 33650469

Hernández-Breijo B, Navarro-Compán V, Plasencia-Rodríguez C, Parodis I, Gehin JE, Martínez-Feito A, Novella-Navarro M, Mezcua A, Warren DJ, Nozal P, Pascual-Salcedo D, Balsa A (2021)
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
Sci Rep, 11 (1), 11632
DOI 10.1038/s41598-021-91177-4, PubMed 34079038

Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876

Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077

Publications 2020

Syversen SW, Goll GL, Jørgensen KK, Olsen IC, Sandanger Ø, Gehin JE, Warren DJ, Sexton J, Mørk C, Jahnsen J, Kvien TK, Bolstad N, Haavardsholm EA (2020)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007

Publications 2019

Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E (2019)
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Arthritis Res Ther, 21 (1), 256
DOI 10.1186/s13075-019-2009-5, PubMed 31783773